We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,643.50 | 1,641.00 | 1,641.50 | 1,648.00 | 1,631.00 | 1,638.50 | 5,186,354 | 16:35:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
LONDON-- GlaxoSmithKline PLC (GSK.LN) said a review of data from a phase III trial of losmapimod for heart treatment "did not indicate efficacy against the primary endpoint and did not support investment in the larger part B of the study as currently designed."
GSK's also said its Advair Diskus achieved its primary endpoint in a safety study of patients with asthma and that its shingles treatment Shingrix demonstrated "90% efficacy against shingles in people 70 years of age and over" in a Phase III trial.
Shares at 1116 GMT, down 3 pence, or 0.2%, at 1,366 pence valuing the company at GBP66.5 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
October 27, 2015 07:32 ET (11:32 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
